Rapamycin combined with roxadustin for the treatment of acquired pure red cell aplasia- a prospective, single-arm, open-lable, multicenter study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065107

Enrollment

Unknown

Registered

2022-10-28

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pure red cell aplasia

Interventions

Treatment Arm:Rapamycin combined with roxadustin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age>=18 years; 2. Confirmed non congenital pure red aplastic anemia; 3. Cardiac function: EF>=45%; Liver function: Total bilirubin <= 3 times the upper normal limit; Glutamate transaminase<= 3 times the upper limit of normal; Cereal grass transaminase<=3 times of normal upper limit; 4. The patient must have the ability to understand and be willing to participate in this study, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Age<18 years; 2. Secondary pure red aplastic anemia without control of this disease; 3. Uncontrolled active infections; 4. Merge severe underlying diseases; 5. Merging active malignant tumors; 6. Patients with severe organ dysfunction and other researchers who consider them unsuitable for enrollment; 7. Pregnant or lactating patients; 8. Refuse to enroll patients in the study.

Design outcomes

Primary

Measure	Time frame
Hemoglobin level (in six months);	—

Secondary

Measure	Time frame
Hemoglobin level (in 1 year);Treatment response obtained for the first time(in days);Adverse effects(assessed acording to CTCAE 5.0);	—

Countries

China

Contacts

Public ContactLimin Liu

Soochow hopes hematonosis hospital

liminliu2006@163.com+86 15262482466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 22, 2026